Protocol Ledger

NCT06409364 · Phase II · RECRUITING

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Interventional Phase II clinical trial protocol NCT06409364 sponsored by The George Institute in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-13 Enrollment: 524 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06409364
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)524 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06409364
Protocol FieldVerified Registry Value
NCT IdentifierNCT06409364
Consolidated Lead SponsorThe George Institute
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment524 participants (ESTIMATED)
Registered Start Date2025-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06409364
Hospital Research SiteLocationSite Profile
Royal North Shore HospitalSt Leonards, AustraliaOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI